DE69827777D1 - Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie - Google Patents

Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie

Info

Publication number
DE69827777D1
DE69827777D1 DE69827777T DE69827777T DE69827777D1 DE 69827777 D1 DE69827777 D1 DE 69827777D1 DE 69827777 T DE69827777 T DE 69827777T DE 69827777 T DE69827777 T DE 69827777T DE 69827777 D1 DE69827777 D1 DE 69827777D1
Authority
DE
Germany
Prior art keywords
hyperlipidemia
delayed
treatment
release compositions
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69827777T
Other languages
English (en)
Other versions
DE69827777T2 (de
DE69827777T9 (de
DE69827777T3 (de
Inventor
Michael Myers
P Sanghvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant International Bermuda
Original Assignee
Biovail International Ltd Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11041609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69827777(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail International Ltd Ireland filed Critical Biovail International Ltd Ireland
Publication of DE69827777D1 publication Critical patent/DE69827777D1/de
Publication of DE69827777T2 publication Critical patent/DE69827777T2/de
Application granted granted Critical
Publication of DE69827777T3 publication Critical patent/DE69827777T3/de
Publication of DE69827777T9 publication Critical patent/DE69827777T9/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
DE69827777T 1997-10-07 1998-07-20 Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie Active DE69827777T9 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE19970731A IE970731A1 (en) 1997-10-07 1997-10-07 Product and method for the treatment of hyperlipidemia
IE970731 1997-10-07
PCT/IB1998/001489 WO1999017774A1 (en) 1997-10-07 1998-07-20 Product and method for the treatment of hyperlipidemia

Publications (4)

Publication Number Publication Date
DE69827777D1 true DE69827777D1 (de) 2004-12-30
DE69827777T2 DE69827777T2 (de) 2005-12-22
DE69827777T3 DE69827777T3 (de) 2010-07-29
DE69827777T9 DE69827777T9 (de) 2010-11-11

Family

ID=11041609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69827777T Active DE69827777T9 (de) 1997-10-07 1998-07-20 Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie

Country Status (9)

Country Link
US (1) US6090830A (de)
EP (1) EP0969838B2 (de)
AT (1) ATE283050T1 (de)
AU (1) AU8995598A (de)
CA (1) CA2273298C (de)
DE (1) DE69827777T9 (de)
ES (1) ES2235357T5 (de)
IE (1) IE970731A1 (de)
WO (1) WO1999017774A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP1117384A1 (de) * 1998-10-01 2001-07-25 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7503493B2 (en) * 1999-10-25 2009-03-17 Silverbrook Research Pty Ltd Method and system for digitizing freehand graphics with user-selected properties
CN1387430A (zh) * 1999-11-03 2002-12-25 霍华德·J·史密斯及同仁控股有限公司 肝脏的选择性治疗
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
ATE464880T1 (de) * 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
MXPA04009033A (es) * 2002-03-18 2005-01-25 Pharmacia Corp Combinacion de un antagonista de receptor de aldosterona y acido nicotinico o un derivado de acido nicotinico.
US20040033202A1 (en) * 2002-06-10 2004-02-19 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and novel sterol combinations
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1889933A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 由基于液体的工艺制备的阿奇霉素多颗粒剂型
EP1691786A1 (de) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiteilchenförmige zusammensetzungen mit verbesserter stabilität
KR20080064209A (ko) * 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
DK1691787T3 (da) * 2003-12-04 2008-09-22 Pfizer Prod Inc Fremgangsmåde til at danne småpartikler
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1689368B1 (de) * 2003-12-04 2016-09-28 Bend Research, Inc Sprüherstarrungsverfahren mit einem extruder zur herstellung von multiteilchenförmigen kristallinen arzneimittelzusammensetzungen
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
PL1919466T3 (pl) 2005-07-11 2012-05-31 Cortria Corp Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
JP2009527577A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム医薬組成物
ES2418153T3 (es) * 2006-03-08 2013-08-12 Cortria Corporation Terapia de combinación con inhibidores no selectivos de COX para prevenir lesiones gástricas relacionadas con COX
WO2008127893A1 (en) * 2007-04-04 2008-10-23 Hight H Thomas Niacin-based pharmaceutical compositions
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
WO2010010579A1 (en) * 2008-07-19 2010-01-28 Lupin Limited Multiple unit dosage form of niacin
CN101836987B (zh) * 2009-03-19 2013-03-27 西安万隆制药股份有限公司 一种复方烟酸缓释片
US20190111064A1 (en) * 2017-10-18 2019-04-18 Interstice Therapeutics, LLC Statin + vitamin d combination drug and method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1255805A (en) * 1967-12-16 1971-12-01 Albert Ag Chem Werke Improvements in delayed release pharmaceutical preparations and stabilisation of vitamins
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5458823A (en) * 1994-10-28 1995-10-17 Fuisz Technologies Ltd. Method and apparatus for spinning feedstock material
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
CA2298549C (en) † 1997-07-31 2006-01-10 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night

Also Published As

Publication number Publication date
AU8995598A (en) 1999-04-27
DE69827777T2 (de) 2005-12-22
ATE283050T1 (de) 2004-12-15
CA2273298C (en) 2008-04-08
EP0969838B2 (de) 2010-01-13
EP0969838B1 (de) 2004-11-24
CA2273298A1 (en) 1999-04-15
EP0969838A1 (de) 2000-01-12
DE69827777T9 (de) 2010-11-11
US6090830A (en) 2000-07-18
ES2235357T5 (es) 2010-03-30
WO1999017774A1 (en) 1999-04-15
IE970731A1 (en) 2000-10-04
DE69827777T3 (de) 2010-07-29
ES2235357T3 (es) 2005-07-01

Similar Documents

Publication Publication Date Title
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DE69907977D1 (de) Pyrrolobenzodiazepine
ATE164593T1 (de) Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
MX9308199A (es) Inhibidores de enzima.
DE69827821D1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
DE69621021D1 (de) Inhibitoren der plättchenaggregation
ATE247470T1 (de) Neue substituierte imidazolverbindungen
IT8922768A0 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
NO996578L (no) Urokinase-inhibitorer
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
EP0529854A3 (en) Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as hmg-coa reductase inhibitors
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
BR9711586A (pt) Compostos e uso dos mesmo
DK0888323T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
ES2146249T3 (es) Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
GB9907571D0 (en) Compounds
NO911999L (no) Anvendelse av substituerte beta-hydroksyetylaminer som potente hemmestoffer til exoenzymer i sopp.
NO20003758L (no) Trekonserveringsmidler
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
BR0209776A (pt) Composições de inibidores seletivos de ciclo oxigenase-2 e radiação para inibição ou prevenção de doença cardiovascular
AR005866A1 (es) Composicion farmaceutica antioxidante
MX9204528A (es) 0etodo para tratar el sindrome premenstrual mediante administracion de un inhibidor de la enzima de conversion de angiotensina.
NO882724D0 (no) Smertepreparat.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BIOVAIL LABORATORIES INTERNATIONAL S.R.L., WEL, BB

8366 Restricted maintained after opposition proceedings